Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis’ Inotersen NDA Accepted for Priority Review by the FDA

PDUFA date of July 6, 2018 CARLSBAD, Calif. , Jan. 8, 2018 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration ( FDA ).